Navigation Links
DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
Date:7/19/2011

SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer 4.3, the latest version of the company's flagship solution for patient enrollment planning, tracking and forecasting.

By providing greater visibility into site performance and cost projections, StudyOptimizer 4.3 significantly improves the ability of global pharmaceutical customers to optimize enrollment plans and deliver clinical trials on time and on budget. And with added support for clustered deployments, enterprise customers get improved performance and reliability, particularly for larger global implementations.

"Drug manufacturers are under increasing market pressure to improve enterprise agility, develop drugs faster, and lower costs," said Alan Louie, Research Director at IDC Health Insights. "The key to enabling effective clinical development transformation is improved operational excellence, in large part driven by better access to and exploitation of organizational data at all levels of the organization. DecisionView is one of the technology vendors delivering on this promise by providing real-time access to clinical enrollment performance data and supporting actionable analytics to reduce risk and increase speed in strategic decision making at all levels of the organization."

StudyOptimizer 4.3 delivers the following compelling new capabilities:

Trial Cost Visibility

The Enrollment & Treatment Cost Analysis capabilities automatically calculate planned, current and projected costs based on assumptions entered for each country participating in a trial. This analysis is presented visually, showing these cost elements over time at specific milestone points (such as Last Patient Screened and Last Patient Randomized), and broken down across regions and countries. Intuitive cost visualization adds significant value by enabling users to quickly assess costs at a glance, which is particularly useful for trials where an over-enrollment strategy is employed.

Site Performance Insights

The StudyOptimizer 4.3 'Sites View' feature has been enhanced to include additional insights on the most recent screening and randomization activity for each site, so trial managers can quickly assess which sites are encountering enrollment problems.

Enhanced scalability and performance

With the StudyOptimizer 4.3 release, customers can now run the application distributed across multiple "cluster nodes" simultaneously, providing improved performance and reliability, particularly for larger implementations.

Global Visibility Into Trial Performance

In StudyOptimizer 4.3, customers have portal-based access to two key charts:


"StudyOptimizer has quickly become a trusted 'source of truth' for our customers because it provides up-to-date information about where trial enrollment is, where it's supposed to be, and where it will end up – all in one place," said Linda Drumright, President and Chief Executive Officer at DecisionView. "StudyOptimizer 4.3 deepens that source of truth by providing visibility into additional key areas.  Now users can evaluate performance on a cost basis as well as time, diagnose site performance more granularly, and share StudyOptimizer information across the enterprise more readily through their enterprise portal strategies."

ABOUT DECISIONVIEW

DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 8 of the top 10 global pharmaceutical companies, and has been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to http://www.decisionview.com or call 415-538-1800.


'/>"/>
SOURCE DecisionView Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView Launches StudyOptimizer(TM) 4
2. DecisionView to Create Clinical Trial Enrollment Benchmarks
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
5. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
6. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
7. ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations
8. Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities
9. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Ethicon* today ... Medical, Inc., a privately held medical device company ... System for the surgical treatment of Gastroesophageal Reflux ... strategy of expanding its portfolio of minimally invasive ... medical conditions. Financial terms of the transaction have ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 23, 2017  A new genetic test has ... of individuals who carry HLA-B*15:02 and ... yet potentially deadly side effect of certain medications ... gene HLA-B*15:02 is strongly associated with ... syndrome and toxic epidermal necrolysis in patients treated ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... of SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one ... critical information securely from multiple locations. For the first time, employees can access ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home ... world to manage stress and anxiety. , “Buzzies change the way we interact ... co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint Solution ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National ... sleep is likely not the only cause of the sunken-eye look, which can include ... look older or in poor health are likely due to genetics, dehydration, allergies, and ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
Breaking Medicine News(10 mins):